Heron Therapeutics
HRTX
197 hedge funds and large institutions have $1.16B invested in Heron Therapeutics in 2021 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 74 increasing their positions, 45 reducing their positions, and 14 closing their positions.
137% more call options, than puts
Call options by funds: $3.56M | Put options by funds: $1.51M
64% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 45
64% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 14
4.46% more ownership
Funds ownership: 102% → 106.46% (+4.5%)
4% more funds holding
Funds holding: 189 → 197 (+8)
28% less capital invested
Capital invested by funds: $1.61B → $1.16B (-$450M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$26.9M |
| 2 |
State Street
Boston,
Massachusetts
|
+$21.7M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$16.5M |
| 4 |
Goldman Sachs
New York
|
+$11.1M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$10.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$21.9M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$20.1M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$15.7M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$7.2M |
| 5 |
D.E. Shaw & Co
New York
|
-$6.48M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
201
Russell Investments Group
London,
United Kingdom
| – | -$2.01M | -129,458 | Closed |
|
|
CC
202
Centiva Capital
New York
| – | -$268K | -17,296 | Closed |
|
|
BWCS
203
Beirne Wealth Consulting Services
Shelton,
Connecticut
| – | -$196K | -12,500 | Closed |
|
|
CM
204
Capula Management
Grand Cayman,
Cayman Islands
| – | -$157K | -10,105 | Closed |
|
205
Group One Trading
Chicago,
Illinois
| – | -$94K | -7,721 | Closed |
|
|
SO
206
STRS Ohio
Columbus,
Ohio
| – | -$94K | -6,100 | Closed |
|
|
TFA
207
Toth Financial Advisory
Leesburg,
Virginia
| – | -$1K | -85 | Closed |
|
|
BWA
208
BDO Wealth Advisors
Jacksonville,
Florida
| – | -$1K | -50 | Closed |
|
|
QCG
209
Quadrant Capital Group
Cincinnati,
Ohio
| – | -$1K | -33 | Closed |
|
HRTX Hedge Fund Activity: Q3 2021 in Review
197 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q3 2021, worth a combined $1.16B — down 28% from $1.61B a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new HRTX positions and 14 closed out — a net gain of 9 holders — while 74 added to existing stakes and 45 trimmed.
The largest buyer was UBS O'Connor, adding an estimated $26.9M. The largest seller was Wellington Management Group, cutting an estimated $21.9M.
- 197 institutional investors held Heron Therapeutics (HRTX) as of Q3 2021, up from 189 in Q2 2021.
- Funds reported $1.16B of Heron Therapeutics stock for Q3 2021, down 28% quarter-over-quarter.
- 23 funds opened new Heron Therapeutics positions in Q3 2021 and 14 closed out, a net change of +9 holders.
- The largest Heron Therapeutics buyer in Q3 2021 was UBS O'Connor, an estimated $26.9M added.
- The largest Heron Therapeutics seller in Q3 2021 was Wellington Management Group, an estimated $21.9M sold.
Based on aggregated 13F filings for Q3 2021.